Study of BMS-986158 in Subjects With Select Advanced Cancers

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

83

Participants

Timeline

Start Date

June 19, 2015

Primary Completion Date

March 17, 2021

Study Completion Date

March 17, 2021

Conditions
Advanced Tumors
Interventions
DRUG

BMS-986158

Specified dose on specified days

BIOLOGICAL

Nivolumab

Specified dose on specified days

Trial Locations (13)

3004

Nucleus Network, Melbourne

19104

Univ. Of Pa, Philadelphia

28050

Centro Integral Oncologico Clara Campal, Madrid

29605

Institute for Translational Oncology Research-ITOR, Greenville

31008

Clinica Universidad de Navarra, Pamplona

69373

Local Institution, Lyon

80045

University Of Colorado, Aurora

91010

City Of Hope National Medical Center, Duarte

94800

Local Institution, Villejuif

97239

Oregon Health & Science University, Portland

02215

Dana Farber Cancer Institute., Boston

K1H 8L6

The Ottawa Hospital Cancer Centre, Ottawa

08035

H. Univ. Vall dHebron, Barcelona

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT02419417 - Study of BMS-986158 in Subjects With Select Advanced Cancers | Biotech Hunter | Biotech Hunter